Bristol Myers’ combo hits a roadblock in PhIII kidney test as the search to rival Keytruda continues

Bristol Myers Squibb has hit a snag in its Phase III trial investigating the company’s Opdivo and Yervoy combo in renal cell carcinoma, or RCC.

Researchers had been investigating Opdivo and Yervoy together as a potential treatment for patients who have undergone a full or partial removal of their kidney and who are at a higher risk of a relapse. But in a release Friday, part A of its Phase III study, dubbed CheckMate -914, “did not meet the primary endpoint of disease-free survival,” the company said.

Bristol Myers stated it will complete a full evaluation of the available data and work with investigators on the trial further.

“We are disappointed that the final analysis of CheckMate -914 Part A did not show this same benefit for the post-surgical treatment of patients with localized RCC. Nonetheless, we are dedicated to continuing research and advancing cancer care for all patients with…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*